Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702930 | 0.84 | — | — | |
| SCHEMBL28604611 | 0.78 | TAAR1 (0.36) | TDP1 | |
| SCHEMBL5420712 | 0.75 | MAPT (0.35) | MAPTHPGDSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL379621 | 0.71 | TSHR (0.41) | MAPTHPGDSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL8649739 | 0.71 | CA4 (0.35) | MAPTHPGDSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL28804974 | 0.71 | TSHR (0.41) | MAPTHPGDSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL780943 | 0.71 | TAAR1 (0.39) | TDP1 | |
| SCHEMBL2530002 | 0.69 | DPP4 (0.39) | — | |
| Water SCHEMBL28841261 | 0.69 | TSHR (0.39) | MAPTHPGDSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL23701261 | 0.68 | L3MBTL1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2011834-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2012-07-25 | — | — | EP | claimed |
| CN-107428891-B | Curable composition | 施敏打硬株式会社 | 2021-04-20 | — | — | CN | disclosed |
| CN-108140887-B | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery | 株式会社艾迪科 | 2021-03-12 | — | — | CN | disclosed |
| CN-105392845-B | Photocurable composition | 思美定株式会社 | 2020-10-20 | — | — | CN | disclosed |
| EP-3081612-B1 | PHOTOCURABLE COMPOSITION HAVING ADHESIVE PROPERTIES | CEMEDINE CO LTD (JP) | 2018-11-14 | — | — | EP | disclosed |
| CN-107428891-A | Curable composition | 施敏打硬株式会社 | 2017-12-01 | — | — | CN | disclosed |
| US-9718999-B2 | Photocurable composition having adhesive properties | CEMEDINE CO., LTD (JP) | 2017-08-01 | — | — | US | disclosed |
| US-20160312089-A1 | PHOTOCURABLE COMPOSITION HAVING ADHESIVE PROPERTIES | CEMEDINE CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3081612-A1 | PHOTOCURABLE COMPOSITION HAVING ADHESIVE PROPERTIES | Cemedine Co., Ltd. (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-20160152783-A1 | PHOTOCURABLE COMPOSITION | CEMEDINE CO., LTD. (JP) | 2016-06-02 | — | — | US | disclosed |
| US-7087776-B2 | Silanol enzyme inhibitors | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-08-08 | — | — | US | disclosed |
| US-6960678-B2 | Silanol enzyme inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1019533-B1 | SILANOL ENZYME INHIBITORS | UNIV NEW YORK STATE RES FOUND (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050171059-A1 | Silanol enzyme inhibitors | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK. | 2005-08-04 | — | — | US | disclosed |
| US-20030096793-A1 | Inhibit protease enzymes; Benzyl 5-(benzoylamino)-4,4-dihydroxy-7- methyl-4-sila-octanamide, for example can be used to inhibit HIV protease in the treatment of AIDS | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2003-05-22 | — | — | US | disclosed |
| US-6441212-B1 | SILANEDIOL TRIMER OR LARGER MOIETY CONTAINING AT LEAST ONE AMINO OR AMIDO GROUP; ISOSTERES THAT ASPARTIC PROTEASES ACT UPON; NOT CLEAVED UNDER ENZYMATIC CONDITIONS; HUMAN IMMUNODEFICIENCY VIRUS | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2002-08-27 | — | — | US | disclosed |
| EP-1019533-A4 | SILANOL ENZYME INHIBITORS | UNIV NEW YORK STATE RES FOUND (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-1019533-A1 | SILANOL ENZYME INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5760019-A | INHIBIT PROTEASE ENZYMES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1998002578-A1 | SILANOL ENZYME INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096793-A1 | Inhibit protease enzymes; Benzyl 5-(benzoylamino)-4,4-dihydroxy-7- methyl-4-sila-octanamide, for example can be used to inhibit HIV protease in the treatment of AIDS | CTSE, CTSS, DNPEP | MAPT 4681/4885HPGD 1353/4885SMN1; SMN2 4548/4885 |
| US-20050171059-A1 | Silanol enzyme inhibitors | CMA1, CTSS, SERPINB1 | MAPT 4747/4885HPGD 1121/4885SMN1; SMN2 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.